구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dendritic Cell Tumor Peptide Vaccine (Dendritic Cell Tumor Peptide Vaccine) Universidad Nacional de Colombia·Diffuse Hemispheric Glioma, H3 G34… 54 trials |
|---|---|
Overview Program | Dendritic Cell Tumor Peptide Vaccine |
Overview Company | Universidad Nacional de Colombia |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Hemispheric Glioma, H3 G34-Mutan |
Overview Indication | Diffuse Hemispheric Glioma, H3 G34-Mutant |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical Safety signal | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical Reported PFS | 19 |
Clinical Reported OS | 52 |
Clinical Result source | ClinicalTrials.gov NCT02151448 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02151448 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dendritic Cell Tumor Peptide Vaccine (Dendritic Cell Tumor Peptide Vaccine) Universidad Nacional de Colombia·Diffuse Hemispheric Glioma, H3 G34… 54 trials |
|---|---|
Overview Program | Dendritic Cell Tumor Peptide Vaccine |
Overview Company | Universidad Nacional de Colombia |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Hemispheric Glioma, H3 G34-Mutan |
Overview Indication | Diffuse Hemispheric Glioma, H3 G34-Mutant |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical Safety signal | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical Reported PFS | 19 |
Clinical Reported OS | 52 |
Clinical Result source | ClinicalTrials.gov NCT02151448 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02151448 |
추천 비교
추천 비교